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Objectives: Characterize the real-world management of and outcomes for children with
epilepsy receiving rescue medication for prolonged acute convulsive seizures (PACS) in the
community.
Methods: PERFECT-3 (Practices in Emergency and Rescue medication For Epilepsy managed
with Community-administered Therapy 3) was a European, retrospective observational
study. Eligible patients were non-institutionalized children with epilepsy aged 3e16 years
who had experienced 1 PACS in the past year and had 1 currently prescribed PACS
rescue medication. Investigators provided clinical assessments and parents/guardians
completed questionnaires. Statistical tests were post hoc; p values are descriptive.
Results: At enrollment (N ¼ 286), most patients had prescriptions for diazepam (69.2%) and/
or midazolam (55.9%); some had two (26.6%) or three (2.4%) prescribed rescue medications.
Most patients experienced PACS despite regular anti-epilepsy medication. According to
parents, the average duration of their child's seizures without rescue medication was
<5 min in 35.7% of patients, 5e<20 min in 42.6%, and 20 min in 21.7% (n ¼ 258);
with rescue medication seizure duration was <5 min in 69.4% of patients, 5e<20 min in
25.6%, and 20 min in 5.0%. Rescue medication use was significantly associated with
average seizures lasting <5 min (c2 ¼ 58.8; p < 0.0001). At the time of their most recent
PACS, 58.5e67.8% of children reportedly received rescue medication within 5 min of
seizure onset, and 85.4e94.1% within 10 min.uroscience, Bambino Gesu` Children's Hospital, Piazza S. Onofrio, 4, 00165 Rome, Italy.
et (F. Vigevano).
d The Authors. Published by Elsevier Ltd on behalf of the European Paediatric Neurology
the CC BY license (http://creativecommons.org/licenses/by/4.0/).
e u r o p e a n j o u r n a l o f p a e d i a t r i c n e u r o l o g y 2 2 ( 2 0 1 8 ) 5 6e6 3 57Conclusion: This study provides the first real-world data that rescue medications adminis-
tered in the community reduce the duration of PACS in children with epilepsy. Study
limitations including potential recall bias are acknowledged.
© 2017 Shire Development LLC and The Authors. Published by Elsevier Ltd on behalf of the
European Paediatric Neurology Society. This is an open access article under the CC BY li-
cense (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Most seizures experienced by children with epilepsy stop
spontaneously within 5 min, but prolonged seizures lasting
longer than 5 min are likely to progress to status epilepticus
without treatment.1 Convulsive status epilepticus can cause
irreversible neurological damage and death (mortality about
3e5%), and requires early treatment to control seizures and
improve outcomes.2 Status epilepticus is conceptually defined
as a seizure lasting 30 min or more, but operationally defined
(for the purposes of administration of emergency treatment)
as a seizure lasting 5 min or more.3 Patients may need to have
their rescue medication administered to them outside of the
professional healthcare environment, including at home, at
school, or in other community settings. Randomized
controlled studies have shown that benzodiazepine rescue
medications terminate seizures when given in the emergency
department4 or by paramedics.5 Despite widespread pre-
scription for community use, there is only sparse evidence
that rescue medication administered to children by parents,
teachers, or other caregivers reduces seizure duration and
prevents status epilepticus. Clinical guidelines offer few rec-
ommendations regarding whether and when community
caregivers should administer rescue medication.6 The few
studies of home use of rescue medication that compared
treated and untreated seizures have focused on emergency
hospital admissions7 or the frequency of acute repetitive
seizures.8,9
PERFECT-3 (Practices in Emergency and Rescuemedication
For Epilepsy with Community-administered Therapy 3) was a
large-scale European study that was designed to provide real-
world evidence about how prolonged acute seizures (PACS)
are managed at home, at school, and in the wider community
from the perspective of paediatric patients, their parents/
guardians, and their physicians. Here, we characterize PACS
rescuemedication use and the outcome of seizure duration in
children receiving rescue medication in the community. The
value of this real-world information about the use of rescue
medication, together with the limitations of the study,
including recall bias, are discussed.2. Methods
2.1. Design
PERFECT-3 was a European, retrospective, observational,
survey-based study of the real-world management of PACSfrom the perspective of patients, caregivers and physicians.
Eligible patients were non-institutionalized children (aged
3e16 years) who had been diagnosed with epilepsy at least 12
months previously, had experienced one or more PACS in the
past 12months, and had one ormore current prescriptions for
PACS rescue medication. PACS were defined as clinically
registered convulsive seizures lasting longer than 5 min. Pa-
tients with pseudoseizures, other nonepileptic events, or
febrile convulsions with no diagnosis of epilepsy were
excluded from the study.
2.2. Ethics and conduct
The study was conducted from July 2013 to May 2014 in
accordance with the International Conference on Harmo-
nisation of Good Clinical Practice, the Declaration of Helsinki,
and local ethical and legal requirements for non-
interventional studies (where applicable).
Patients were identified by consecutive sampling of eligible
children attending their usual centre visits. After obtaining
informed consent from parents/guardians and assent from
children aged 7e16 years, physicians registered eligible pa-
tients from 20 specialist paediatric neurology centres and
paediatric departments in Germany, Italy, Spain, and the UK.
The planned sample size was 20 patients from each study
centre; a nationally representative patient sample was sought
from each participating country. The web-based system
allowed enrollment of patients only if the quota for their age
group (3e6 years, 7e12 years, and 13e16 years at study
enrollment) in each country had not been filled.
2.3. Assessments
Demographic, medical history, and treatment information,
including prescribed PACS rescue medications, were extrac-
ted from patients' medical records and entered into a web-
based system by site staff. Web-based questionnaires were
completed by investigators (13 questions) and parents/
guardians (110 questions) to document their experience of
caring for children with PACS in the community. Epilepsy
aetiology responses from investigator questionnaires were
classified according to the latest terminology recommended
by the International League Against Epilepsy (ILAE).10 The
recall period for questions in the survey was up to 12 months.
In the case of missing responses, parents/guardians and in-
vestigators were prompted by email reminders through the
web-based system to complete all questions. All web-based
questionnaires were completed at the convenience of the
parent/guardian and were available from any computer with
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obtained using a key and URL provided by the study centre.
Other measures included in this study were patient/proxy
questionnaires and quality-of-life instruments (results to be
reported in a subsequent publication).
2.4. Data analysis
This observational study had no pre-specified primary
endpoint. Analyses were performed for all enrolled patients
with survey data entered into the web-based system; incom-
plete questionnaires were not analyzed. The duration of sei-
zures both without rescue medication and when rescue
medication was given was obtained from parents' responses
to two survey questions: ‘When your child experiences a
prolonged seizure, on average how long does it last when no
rescue medication has been given?’ and ‘When your child
experiences a prolonged seizure, on average how long does it
last after rescuemedication has been given?’. Responses were
based on parental recollections from the previous 12 months.
The available response categorieswere: 0e<5min, 5e<10min,
10e<15 min, 15e<20 min, or 20 min. Statistical tests (c2)
were conducted post hoc, and p values are descriptive.3. Results
3.1. Patients
Clinical data were extracted from medical records for all 286
enrolled children (Germany, n ¼ 92; Italy, n ¼ 75; Spain, n ¼ 77;
UK, n ¼ 42) (Table 1). Questionnaires were completed by in-
vestigators for 281 children and by parents/guardians for 258
children (Table 1). Enrolled patients were aged 3e16 years
(median, 8) and 54.9% were boys (Table 1). According to
investigator responses (N ¼ 281), epilepsy aetiology wasTable 1 e Patient demographics, clinical characteristics, and d
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Investigator reported epilepsy aetiology
Genetic, n (%) 86 (30.6) 28 (30.8)
Structural, n (%) 84 (29.9) 35 (38.5)
Other/unknown, n (%) 106 (37.7) 23 (25.3)
Metabolic, n (%) 5 (1.8) 5 (5.5)
PACS ¼ prolonged acute convulsive seizures; SD ¼ standard deviation.genetic in 30.6% of patients, structural in 29.9%, other/un-
known in 37.7%, and metabolic in 1.8% (Table 1). Nearly all
patients (96.4%; N ¼ 281) were receiving prescribed anti-
epileptic medication at the time of study entry; 26.3% were
receiving monotherapy, 40.2% were receiving bitherapy, and
29.9% had 3 or more anti-epileptic drugs prescribed. Pre-
scribed anti-epileptic drugs included valproic acid (47.7%),
levetiracetam (28.5%), clobazam (23.8%), lamotrigine (17.8%),
topiramate (17.8%), and oxcarbazepine (13.2%), and 16.0%
were receiving non-pharmacological treatment (ketogenic
diet, vagus nerve stimulation, or unknown/other). Despite
receiving regular anti-epilepsy medication, most patients
(199/258; 77.1%) continued to experience PACS that lasted
longer than 5 min and required rescue medication, according
to parents.
3.2. PACS frequency
At study entry, patients had experienced 1e400 PACS in the
past 12 months; 8 patients had experienced more than 200
PACS (Table 1). A skewed distribution of PACS frequency was
observed in the parent survey (Fig. 1A); 44.9% of patients had
experienced fewer than 2 or 3 PACS in the past 12months, and
3.9% had experienced several PACS a day (N ¼ 258). A skewed
distribution of PACS frequency was also observed in medical
record extracts (data not shown).
3.3. Prescribed rescue medications
Overall, 69.2% of enrolled children had prescriptions for
diazepam and 55.9% for midazolam at study entry; some had
two (26.6%) or three (2.4%) prescribed rescue medications
(Fig. 1B) (N ¼ 286). The formulation was buccal, rectal, or other
for 5.1%, 77.3%, and 17.7% of the 198 diazepam prescriptions
and 91.3%, 0.6%, and 7.5% of the 160midazolam prescriptions,
respectively. Other rescue medications prescribed includedisposition.


























26 (35.1) 21 (28.0) 11 (26.8)
17 (23.0) 21 (28.0) 11 (26.8)
31 (41.9) 33 (44.0) 19 (46.3)
0 (0.0) 0 (0.0) 0 (0.0)
Fig. 1 e (A) PACS frequency in the past 12 months, from the parent survey; and (B) prescribed PACS rescue medication(s) at
study entry, from medical records. Other rescue medications were lorazepam (10 patients), paraldehyde (1 patient), and
unspecified rescue medication (7 patients). PACS ¼ prolonged acute convulsive seizures.
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patterns differed across countries (Fig. S.1).
3.4. Average duration of seizures with and without
rescue medication
Parents of 258 of the 286 enrolled patients completed the
parent questionnaire. According to parental recollections, of
the 166 children whose average untreated seizures lasted
5min or longer, 141 (84.9%) shifted to a shorter average seizure
duration category when given rescue medication, and treated
seizures lasted an average of less than 5 min in 91 (54.8%).
Shifts in average seizure duration per child with and without
rescue medication are represented in Table 2. Rescue medi-
cation was significantly associated with average seizures
lasting less than 5 min, compared with seizures lasting 5 min
or longer (c2 ¼ 58.8; p < 0.0001). Overall, parents reported that
average seizures lasted 20 min or longer in 56/258 children
(21.7%) without rescue medication and 13/258 (5.0%) when
rescue medication was given (Fig. 2A). In each of the fourcountries, a smaller proportion of children had seizures last-
ing more than 20 min and a greater proportion had seizures
lasting under 5 min when they received rescue medication
than when their seizures were not treated (Fig. S.2).
3.5. Administration of rescue medication in the
community
Data on children's most recent PACS were available for 253 of
the 258 patients in the parent survey. Parents reported that
similar proportions of children received rescue medication at
the time of their most recent seizure regardless of the loca-
tion. Rescuemedicationwas given at the time of the seizure to
118/171 (69.0%) of children who had their most recent PACS at
home, 24/32 (75.0%) at school, and 41/50 (82.0%) elsewhere
(Fig. 2B). Of these patients, 58.5e67.8% reportedly received
rescue medication within 5 min of seizure onset, and
85.4e94.1% within 10 min.
As a result of the training and information they had
received, 248/258 (96.1%) of parents felt at least moderately
Table 2 e Shifts in parent-reported average seizure duration category for each child with and without rescue medication.
Average duration of child's seizure, n (%)
Without rescue
medication
When rescue medication has been given
All, n 0 to <5 min 5 to <10 min 10 to <15 min 15 to <20 min 20 min
0 to <5 min 92 88 (95.7) 2 (2.2) 1 (1.1) 0 (0.0) 1 (1.1)
5 to <10 min 71 59 (83.1) 8 (11.3) 2 (2.8) 1 (1.4) 1 (1.4)
10 to <15 min 22 16 (72.7) 5 (22.7) 0 (0.0) 1 (4.5) 0 (0.0)
15 to <20 min 17 6 (35.3) 5 (29.4) 5 (29.4) 1 (5.9) 0 (0.0)
20 min 56 10 (17.9) 16 (28.6) 11 (19.6) 8 (14.3) 11 (19.6)
All, n 258 179 36 19 11 13
A parent of each patient was asked how long their child's seizures lasted on average, both without rescue medication and when rescue
medication had been given. Available responses were: 0 to <5, 5 to <10, 10 to <15, 15 to <20, or 20 min. Grey background shading indicates no
change in parent-reported average seizure duration category. Grey text indicates an increase and black text indicates a decrease in the parent-
reported average seizure duration category when rescue medication was given compared with when it was not given.
e u r o p e a n j o u r n a l o f p a e d i a t r i c n e u r o l o g y 2 2 ( 2 0 1 8 ) 5 6e6 360confident about their ability to effectively administer rescue
medication. Information was not collected about care plans
for individual patients, including how long parents/carers
had been advised to wait before administering rescue
medication.Fig. 2 e (A) Parent-reported average seizure duration for each chi
and (B) rescue medication administration in the community for
indicated numbers of responses to each question in the parent4. Discussion
This large study in four European countries provides the first
real-world data that administration of rescue medication byld with and without rescue medication (overall population),
children's most recent seizure. Percentages are based on
survey (Panel A, n ¼ 258/258; Panel B, n ¼ 253/258).
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seizure duration among children with epilepsy. Participating
children were non-institutionalized and most experienced
PACS despite receiving regular anti-epilepsy therapy. Their
prescribed rescue medications were mainly diazepam (usu-
ally rectal) and/or midazolam (usually buccal). Parents re-
ported the average duration of their child's seizures when
untreated and when rescue medication was given. Overall,
more seizures lasted less than 5 min when children received
their rescuemedication thanwhen they did not. Furthermore,
fewer seizures lasted longer than 20 min when children
received their rescue medication than when they did not.
Regardless of seizure location (home/school/elsewhere),
about one-quarter of children did not receive the prescribed
rescuemedication for theirmost recent PACS, despite parents'
reports that most of the children's average seizures were
shorter when rescue medication was given than when they
were untreated. Furthermore, about one-third of childrenwho
received rescuemedication did not receive it within 5min and
about one-tenth did not receive it within 10min for their most
recent PACS. Data were not collected about why rescue
medication was not given, or was given only after a certain
amount of time. We speculate that the underlying reasons
may have been concerns about the safety, tolerability, ease of
administration, and social acceptability of the prescribed
rescue medication. A lack of caregiver knowledge on patients'
treatment plans, including the recommended time before
administration of rescue medication after the onset of a
seizure, may also explain why rescue medication was not
administered at all or was not administered within a specific
time interval for particular seizures. It should also be noted
that parental recollections represented their perception of an
‘average seizure’. Therefore, data about specific rescue
medication for each individual seizure were not collected.
Nevertheless, the findings suggest that improved education of
parents, school staff, and other caregivers about the impor-
tance of early treatment according to the physician's recom-
mendations could benefit children who experience PACS, in
all countries and for all rescue medications. This highlights
the need for clear and consistent clinical guidelines on com-
munity use of PACS rescue medication.6
The strengths of this study include the large European
population and the collection of real-world data on non-
institutionalized children with epilepsy whose PACS are
managed by caregivers in the community. However, the lim-
itations of this retrospective observational study should be
taken into consideration. The study sites were generally
specialized neurology centres, which may treat patients with
more severe or frequent seizures than non-specialist paedi-
atric centres, so the results may not be applicable to general
clinical practice. To limit selection bias, the recruitment pro-
cess involved consecutive sampling of eligible patients
attending their routine centre visit. Gender effects were not
investigated in this study, although each country enrolled
approximately even numbers of males and females. Eligible
patients were required to have had at least one PACS in the 12
months before enrollment,meaning that the study population
represented a subset of children with epilepsy. However, theselection criteria allowed recruitment of children with widely
ranging disease severity (1e400 PACS/year), reflecting di-
versity in epilepsy aetiology and clinical practice. Limitations
of the study design prevent further analysis of the disease
types included in the study population. Post hoc stratification
of results by PACS frequency may provide additional insights
into the impact of PACS on patients, caregivers, and health-
care services (to be reported elsewhere).
Parent responses may have been subject to recall bias
because theweb-basedquestionnaires reliedon recollectionof
events that could have occurred in the respondents' absence
and up to 12 months previously. The retrospective, non-
interventional design of the study meant that seizure dura-
tion was assessed using parental perceptions of past treated
and untreated seizures for each child, rather than prospective
measurements in groups of patients. The survey questions did
not prompt parents to enter a value, but rather to select one of
five categories (0e<5, 5e<10, 10e<15, 15e<20, or 20 min) for
the duration of each child's seizures on average, bothwith and
without rescue medication. Asking parents or other commu-
nity caregivers to record the duration of children's seizures as
they occur may present ethical and practical problems, given
that their priorities are to care for andmonitor the child, and to
administer rescue medication and seek emergency medical
attention if appropriate. The possibilities of recall bias or esti-
mation of seizure duration were not eliminated in a study
comparing home use of rectal diazepam and intranasal mid-
azolamusing parent timings of seizure duration.11 Finally, this
non-interventional study was not designed to collect safety
data or to allowcomparisonof specific drug therapies or routes
of administration in terms of their side effects, efficacy, ease of
administration, or social acceptability. Owing to differences in
healthcare service providers and reimbursement models, the
country of recruitment presents a confounding variable for
post hoc comparisons of rescue medications. For example,
midazolam use was highest in the UK and diazepam use
highest in Spain and Italy, likely reflecting thatmidazolamwas
available through the UKNHS at the time of the study. Despite
these limitations, the overall findings are relevant when
considering the optimal management of children who expe-
rience PACS, including training of community caregivers to
prevent status epilepticus, avoid hospitalization, and reduce
the risk of long-term neurological damage.Funding source
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